(S)-4-(4-methyl-3-(1H-tetrazol-5-yl)phenyl)-6-(trifluoromethyl)-6-(4-(5,5,5-trifluoropentyl)phenyl)-5,6-dihydropyridin-2(1H)-one

ID: ALA4863471

Chembl Id: CHEMBL4863471

PubChem CID: 164619549

Max Phase: Preclinical

Molecular Formula: C25H23F6N5O

Molecular Weight: 523.48

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ccc(C2=C(c3nnn[nH]3)C(=O)N[C@@](c3ccc(CCCCC(F)(F)F)cc3)(C(F)(F)F)C2)cc1

Standard InChI:  InChI=1S/C25H23F6N5O/c1-15-5-9-17(10-6-15)19-14-23(25(29,30)31,32-22(37)20(19)21-33-35-36-34-21)18-11-7-16(8-12-18)4-2-3-13-24(26,27)28/h5-12H,2-4,13-14H2,1H3,(H,32,37)(H,33,34,35,36)/t23-/m0/s1

Standard InChI Key:  MVTWMJZSCKPEHW-QHCPKHFHSA-N

Alternative Forms

  1. Parent:

    ALA4863471

    ---

Associated Targets(Human)

MGAT2 Tchem Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (703 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mgat2 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (71 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 523.48Molecular Weight (Monoisotopic): 523.1807AlogP: 5.67#Rotatable Bonds: 7
Polar Surface Area: 83.56Molecular Species: ACIDHBA: 4HBD: 2
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.41CX Basic pKa: CX LogP: 6.34CX LogD: 4.73
Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.31Np Likeness Score: -0.55

References

1. Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P..  (2021)  Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.,  64  (19.0): [PMID:34613725] [10.1021/acs.jmedchem.1c01356]

Source